Research paper published today:
Computer-Assisted and Data Driven Approaches for Surveillance, Drug Discovery, and Vaccine Design for the Zika Virus
Received: 24 September 2019 / Accepted: 15 October 2019 / Published: 16 October 2019
BCX4430 an adenosine nucleoside analog has shown EC50 values in the low μg/mL range (3.8–18.2 μg/mL) in vitro, with favorable selective index values and found to be a selective inhibitor of viral RNA-dependent RNA polymerase (RdRp). The compound has also shown in vivo efficacy in AG129 mouse model of ZIKV. Treating the animals with BCX4430 (300 mg/kg/d) protected seven of eight mice from mortality induced by a Malaysian strain (P 6–740) of ZIKV . This protective efficacy of BCX4430 encourages its further development on the basis of safety and better efficacy evaluations.